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Oxidative stress and inflammation play critical roles
in the development of diabetes and its complications.
Recent studies provided compelling evidence that the
newly discovered lipid signaling system (ie, the endo-
cannabinoid system) may significantly influence reac-
tive oxygen species production, inflammation, and sub-
sequent tissue injury, in addition to its well-known
metabolic effects and functions. The modulation of the
activity of this system holds tremendous therapeutic
potential in a wide range of diseases, ranging from can-
cer, pain, neurodegenerative, and cardiovascular dis-
eases to obesity and metabolic syndrome, diabetes,
and diabetic complications. This review focuses on
the role of the endocannabinoid system in primary
diabetes and its effects on various diabetic complica-
tions, such as diabetic cardiovascular dysfunction, ne-
phropathy, retinopathy, and neuropathy, particularly
highlighting the mechanisms beyond the metabolic
consequences of the activation of the endocannabi-
noid system. The therapeutic potential of targeting
the endocannabinoid system and certain plant-de-
rived cannabinoids, such as cannabidiol and 9-tetra-
hydrocannabivarin, which are devoid of psychotro-
pic effects and possess potent anti-inflammatory
and/or antioxidant properties, in diabetes and dia-
betic complications is also discussed. (Am J Pathol
2012, 180:432–442; DOI: 10.1016/j.ajpath.2011.11.003)
Endocannabinoids (ECs) are endogenous, bioactive lipid
mediators that exert their effects mainly through specific
432G protein–coupled (primarily Gi/o) receptors: cannabi-
noid-1 (CB1) receptor and cannabinoid-2 (CB2) receptor.
The signaling of these receptors is complex and, de-
pending on the cell type, may involve inhibition (also
activation in certain cases) of adenyl cyclase activity,
activation of various mitogen-activated protein kinases
(MAPKs) (eg, p38- and p44/42-MAPKs, c-Jun N-terminal
kinase, and extracellular signal–regulated kinase), pro-
tein kinases A and C, and modulation of various Ca2
and K channels.1–3 Previously, it was thought that the
CB1 receptor was predominantly expressed in the central
nervous system, mediating undesirable psychoactive ef-
fects, whereas the CB2 receptor was expressed mainly in
immune and hematopoietic cells, modulating immune ac-
tivities. However, recent studies also have demonstrated
the expression of these receptors in various other cell
types, both centrally and in the peripheral organs, impli-
cating these receptors in a wide range of physiologic and
pathologic functions and activities.1,4,5 In addition to their
primary target cannabinoid receptors, ECs and possibly
their metabolites may also activate multiple receptor-de-
pendent and -independent mechanisms.3
The two main ECs are anandamide (AEA) and 2-arachi-
donoyl glycerol (2-AG).6,7 They are synthesized “on de-
mand,” not stored in the cell, and are degraded quickly to
have a transient and localized effect.5 Their synthesis is
mainly dependent on intracellular Ca2 concentrations
because AEA is mainly formed via a two-step pathway
composed of a Ca2-dependent N-acyltransferase and
N-acylphosphatidylethanolamine-hydrolyzing phospho-
lipase D, whereas diacylglycerol lipase and phospho-
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2-AG. Their main metabolizing enzymes are fatty acid
hydrolase (FAAH) and monoacylglycerol lipase (MAGL),
the former favoring AEA and the latter favoring 2-AG
catabolism.8 AEA and 2-AG bind to both the CB1 and
CB2 receptors; however, AEA binds with higher affinity to
the CB1 receptor, whereas 2-AG favors the CB2 recep-
tor.1 Because of rapid degradation, ECs and their metab-
olites may also exert multiple, important biological effects
unrelated to the activation of conventional cannabinoid
receptors.1–3 The ECs, their specific receptors, and the
synthesizing and metabolizing enzymes form the EC sys-
tem (ECS).5,8 The modulation of the ECS has therapeutic
potential in a wide range of disparate diseases and
pathologic conditions that affect humans, including neu-
rodegenerative, kidney, and gastrointestinal diseases,
pain, cancer, bone and cardiovascular disorders, obesity
and metabolic syndrome, and inflammation, just to men-
tion a few.1,4,5
The cannabinoid receptors are, at least in part, also re-
sponsible for the effects of several natural constituents of
Cannabis sativa (ie, the marijuana plant).3,9 The most char-
acterized plant-derived cannabinoid, 9-tetrahydrocan-
nabinol (THC), was previously considered the only active
ingredient of marijuana, responsible for its undesirable psy-
chotropic effects mediated by central CB1 receptors,
greatly limiting its potential therapeutic use. Numerous re-
cent studies have also focused on two natural plant-derived
constituents with very negligible psychotropic effects and
great therapeutic potential in inflammatory diseases, diabe-
tes, and diabetic complications: cannabidiol (CBD) and
9-tetrahydrocannabivarin (THCV).3,9 CBD is the most
abundant nonpsychotropic constituent of C. sativa and
has been reported to exert protective effects in multiple
disease models,9 including diabetes10,11 and diabetic
complications.12–15 CBD is well tolerated without adverse
effects when administered in the long term to humans
and has been approved for the treatment of inflammation,
pain, and spasticity associated with multiple sclerosis in
Canada, the United Kingdom, and Spain. THCV seems to
be a promising therapeutic compound because it has been
shown to behave as a CB1 receptor antagonist; at the same
time, it activates CB2 receptors, thereby decreasing inflam-
mation and oxidative stress,16,17 which are key processes
in the development of diabetes and diabetic complications.
Diabetes mellitus affects 8.3% of the US population
and is the seventh leading cause of death in the United
States.18 Type 1 diabetes mellitus (insulin-dependent or
juvenile onset) commonly has an increased prevalence of
autoantibodies against pancreatic islet cells, which are
thought to play an important role in the destruction of
insulin-producing -cells. This type of diabetes is usually
diagnosed in individuals younger than 30 years and has
a prevalence of 0.2% to 0.5%. Patients have a lean body
build and are prone to ketosis, owing to absent insulin
production. Type 2 diabetes (non–insulin-dependent or
maturity onset) is often characterized by a combination of
a progressive insulin secretory defect in pancreatic
-cells and resistance to the effects of insulin in periph-
eral target tissues. This type of diabetes has a prevalence
of 2% to 4% and is more common in men. Patients areusually older than 40 years and obese. Both types of
diabetes are characterized by high blood glucose levels
(hyperglycemia) and consequent metabolic alterations,
which eventually lead to the development of multiple
complications.
Most diabetic complications are associated with patho-
logic alterations in the vascular wall; the most common
macrovascular complication of diabetes is atherosclerosis,
which increases the risk of myocardial infarction, stroke,
and peripheral artery disease, whereas microvascular com-
plications underlie nephropathy, retinopathy, and periph-
eral neuropathy.19 Diabetic complications have tremen-
dous physical, emotional, and economic impact because
diabetes is the leading cause of kidney failure, nontrau-
matic lower-limb amputation, and new cases of blindness
among adults in the United States.18 Hyperglycemia,
caused by either a lack of insulin or insulin resistance,
triggers tissue damage via a multiple complex mecha-
nism, leading to the accumulation of sorbitol and ad-
vanced glycation end products, while increasing the ex-
pression of its receptor. Hyperglycemia also activates
protein kinase C and the hexosamine pathway. Several
studies have indicated that the common upstream event
in the pathogenesis of diabetic complications is the for-
mation of reactive oxygen species (ROS) and reactive
nitrogen species.20,21 We provide a brief overview of the
role of the ECS in the pathogenesis of diabetes and
diabetic complications and the therapeutic potential of
the modulation of this endogenous system and certain
natural (plant-derived) cannabinoids with antioxidant and
anti-inflammatory properties.
Role of the ECS in Diabetes and Diabetic
Complications
Primary Diabetes
Diabetes is characterized by hyperglycemia caused by
either a lack of insulin (due to autoimmune destruction of
islet cells) or insulin resistance. Obesity is the main risk
factor for type 2 diabetes, leading to insulin resistance.
Exogenous cannabinoids and ECs increase food intake
and promote weight gain in animals by activating central
CB1 receptors.
22 Furthermore, activation of the periph-
eral ECS has been observed in human obesity,23 leading
to adipogenesis, lipogenesis, hepatic steatosis, and in-
creased insulin resistance, most likely involving both pe-
ripheral and central CB1 receptors.
24,25 Blockade of CB1
receptors with rimonabant (RIO) has been promising in
clinical trials, leading to weight loss and improvements in
several metabolic risk factors (eg, decreased waist cir-
cumference, increased high-density lipoprotein choles-
terol levels, and decreased triglyceride levels) that can-
not be explained by the observed weight loss.26–28 The
CRESCENDO trial, testing RIO for the prevention of car-
diovascular events, however, was abruptly terminated
because of the drug’s neuropsychiatric adverse ef-
fects.29 However, the fact that a peripheral CB1 receptor
antagonist was also able to efficiently reduce weight and
improve metabolic risk factors in a mouse model of obe-
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a viable option to tackle human obesity.25 Indeed, there
is considerable interest in the development of peripheral
CB1 receptor antagonists.
25
The presence and function of the ECS in islet cells
have been intensively investigated. The results regarding
the expression of cannabinoid receptors have been con-
tradictory and show a strong species dependence. In
mouse islet cells, both CB1 and CB2 receptors are ex-
pressed31–34; however, the specific cell type that ex-
presses these receptors is still under debate. It has also
been shown that EC-synthesizing enzymes are also pres-
ent in -cells, whereas the metabolizing enzymes are
restricted to -cells33,35 with questionable expression of
MAGL in -cells.35 There is consensus that CB1 recep-
tors are expressed in rat pancreatic islets; however, the
presence of CB2 receptors is debated.
32,36,37 MAGL is
expressed in -cells, and FAAH is expressed in -cells.36
More importantly, in the human pancreas, CB1 receptor,
MAGL, and FAAH expression has been confirmed, but
there is no agreement about either their localization or
CB2 receptor expression.
35,36,38 Although there is a lot of
controversy, it seems that most studies agree that CB1
receptors are expressed in islet cells; recently, CB1 re-
ceptor also has been implicated in insulin secretion. A
CB1 receptor agonist was shown to increase insulin se-
cretion in RINm5F cells,39 MIN6 cells,40 rat islet cells,37
and mouse islet cells.34 Similar findings were confirmed
in human islets cells.38 There is only one report that
showed that AEA and a CB1 agonist decreased insulin
production.41 Results regarding the role of the CB2 re-
ceptor in insulin secretion are also contradictory. Al-
though one group found an increase in insulin release on
CB2 receptor activation,
34,40 others have shown its atten-
uation.31,38 CB1 receptor inhibition has recently been re-
ported to increase -cell proliferation, which is exciting
from a therapeutic point of view.35
It seems that the debate has not yet settled about the
exact role of cannabinoids in pancreatic islet cells, and
the conflicting results might be attributable to the different
species and experimental conditions used in these stud-
ies. The most important fact is, however, that clinical trials
are sending a clear message about the role of the ECS in
the pathogenesis of primary diabetes. The first clinical
trial (RIO Diabetes) aimed to clarify the efficacy and
safety of the CB1 antagonist RIO in obese or overweight
patients with type 2 diabetes inadequately controlled by
either metformin or sulfonylureas.42 Patients receiving
RIO treatment showed greater weight loss, reduction in
waist circumference, hemoglobin A1c levels, and fasting
glucose concentrations compared with placebo. There
was also a significant improvement in high-density lipo-
protein cholesterol, triglyceride, and non–high-density li-
poprotein cholesterol levels, as well as in systolic blood
pressure. In drug-naive patients with type 2 diabetes,
RIO showed a similar efficacy and caused significant
improvements in glycemic control, body weight, and met-
abolic profile (SERENADE trial).43 Recently, an interest-
ing study investigated the effects of CB1 antagonist ther-
apy in insulin-treated patients with type 2 diabetes
(ARPEGGIO trial),44 and the addition of RIO to the pa-tients’ standard insulin treatment improved glycemic con-
trol and cardiometabolic risk factors.
The pivotal role of the ECS in the pathogenesis of
diabetes was further supported by elevated EC levels in
diabetic patients. Patients with type 2 diabetes had
higher serum levels of both AEA and 2-AG than did
healthy volunteers,39 and AEA levels were also increased
in the subcutaneous tissues of these individuals.45
There is also considerable interest in the use of certain
natural and similar synthetic cannabinoid ligands to mod-
ulate a wide variety of immune responses, including
T-lymphocyte activation and subsequent cytokine pro-
duction.17,46 THC was shown to attenuate the severity of
autoimmune responses in an experimental model of au-
toimmune diabetes as evidenced by the significantly
lower number of infiltrating lymphocytic cells and re-
duced expression levels of interferon-, interleukin-12,
and tumor necrosis factor- (TNF-).47 The treatment
also preserved pancreatic insulin content and led to
lower blood glucose levels compared with the untreated
diabetic group. Even though THC shows excellent immu-
nosuppressive ability, the psychoactive effects of the
compound limit its usefulness for therapeutic purposes.
This is the reason why the study10 that showed that CBD
exerts similar beneficial effects is crucially important.
CBD reduced the incidence of diabetes in nonobese
diabetic mice, the mouse model of type 1 diabetes. The
effect was paired with reduced insulitis, which was due to
a shift of the immune response from Th1 to Th2 domi-
nance, resulting in decreased levels of proinflammatory
cytokines, such as interferon- and TNF-. CBD was also
able to ameliorate the disease when given at the time of
the development of initial symptoms of diabetes in non-
obese diabetic mice.11
Collectively, even though the ECS seems to play an
important role in the development and control of primary
diabetes, the exact mechanisms and cellular targets are
still not completely understood. In the near future, the role
of cannabinoid receptors in the regulation of islet cell
function must be further investigated, and it is important
to develop a peripheral CB1 receptor antagonist suitable
for clinical trials. Plant-derived cannabinoids, which are
not toxic to humans and devoid of psychoactive effects,
such as cannabidiol, may represent a promising new
avenue to target autoimmune diabetes and protect pan-
creatic -cells from oxidative injury.
Cardiovascular Complications
Accurate glucose, blood pressure, and plasma lipid con-
trols, as well as preventive care practices, are effective in
reducing the number of complications in certain patient
cohorts with diabetes; however, they have their own lim-
itations. For example, although intensive glucose-lower-
ing therapy reduces glycated hemoglobin levels, it in-
creases 5-year mortality compared with standard therapy
(ACCORD trial).48 The understanding of the pathogene-
ses of microvascular and macrovascular complications in
diabetes is paramount for the development of new ther-
apeutic targets. Recently, several studies highlighted the
important role of the ECS in the regulation of vascular
Cannabinoids in Diabetes 435
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suggesting that the modulation of the ECS and the ad-
ministration of plant-derived cannabinoids with antioxi-
dant and anti-inflammatory properties might be beneficial
in the treatment of cardiovascular complications associ-
ated with diabetes.
Both CB1 and CB2 receptors are expressed in the cells
of the cardiovascular system, including cardiomyocytes,
fibroblasts, endothelial and vascular smooth muscle
cells, and infiltrating immune cells.49 CB1 receptor acti-
vation by AEA or synthetic agonists induces ROS pro-
duction, MAPK activation, and cell death in human cor-
onary endothelial cells,50 mimicking the pathogenesis of
diabetes-induced endothelial dysfunction.21 The activa-
tion of MAPK is only partially mediated by ROS, suggest-
ing direct CB1 receptor–mediated MAPK activation. Fur-
thermore, activation of CB1 receptors leads to increased
angiotensin-1 receptor expression and nicotinamide ade-
nine dinucleotide phosphate oxidase activity, which contrib-
ute to ROS production.51 In contrast to CB1 receptor acti-
vation, the activation of the CB2 receptor is coupled with
decreased endothelial cell activation, monocyte-endo-
thelial adhesion, and transendothelial monocyte migra-
tion after TNF- or lipopolysaccharide stimulation,52 hall-
marks of the development of atherosclerosis. Activation
of the CB2 receptor also attenuates TNF-–triggered ac-
tivation of both NF-B and Rho, up-regulation of adhesion
molecules, and increased expression levels of monocyte
chemoattractant protein-1 (MCP-1) in endothelial cells.
CB1 receptor activation by ECs and/or synthetic ligands
also promotes ROS generation, MAPK activation, and
inflammatory responses in macrophages and neutro-
phils,53,54 whereas CB2 receptor activation exerts oppos-
ing functions.4
Vascular smooth muscle proliferation and migration
are also key events in the pathogenesis of atherosclero-
sis and, therefore, in all macrovascular complications of
diabetes. CB1 receptors were suggested to play an im-
portant role in this event because receptor blockade was
able to inhibit vascular smooth muscle proliferation and
migration in response to platelet-derived growth factor
stimulation by inhibiting Ras and extracellular signal–reg-
ulated kinase 1/2 activation.55 The application of a CB2
receptor agonist showed a similar efficacy in the attenu-
ation of vascular smooth muscle proliferation,56 indicat-
ing an opposing role of the cannabinoid receptors in both
endothelial cell activation and vascular smooth muscle
proliferation.
The first direct evidence that cannabinoid receptors
play a key role in the pathogenesis of atherosclerosis
came from an ApoE/ mouse model.57 THC treatment
reduced the development of atherosclerotic plaques and
macrophage content through the activation of CB2 recep-
tors. The antiatherosclerotic properties of THC were as-
sociated with a reduction of the TH1 response and an
inhibition of monocyte/macrophage migration to the site
of inflammation. Later, it was shown that the CB1 receptor
antagonist RIO was also able to inhibit atherosclerosis in
mouse models.58,59 Its beneficial effects paralleled an
improved metabolic profile and a decreased inflamma-tory cytokine level, decreasing thioglycollate-induced
macrophage recruitment.
The relevance of these described findings in metabolic
syndrome was investigated by long-term RIO treatment in
obese Zucker rats.60 RIO was able to attenuate in-
creased systolic blood pressure and metabolic abnor-
malities without altering endothelium-dependent relax-
ation and restored vascular contraction induced by
-adrenergic agonists. RIO also increased cyclooxygen-
ase 2 expression and prostacyclin production in the aor-
tas of obese Zucker rats.61 In a rat model of prediabetic
metabolic syndrome, long-term RIO treatment did not
alter macrovascular response, as shown by the unaltered
endothelial function of aortic rings and the incidence of
ischemic myocardial lesions, but it diminished microvas-
cular complications, reducing the albumin-creatinine ra-
tio, an index of renal vascular function, and the fraction of
sclerotic glomeruli.62
The first clinical trial investigating the potential benefit
of long-term CB1 receptor blockade with RIO on the pro-
gression of atherosclerosis in obese patients with coro-
nary artery disease did not have a clear conclusion
(STRADIVARIUS trial).63 Although RIO failed to alter dis-
ease progression for the primary end point (ie, atheroma
volume), it showed a favorable effect on the secondary
end point (ie, total atheroma volume). Additional post hoc
exploratory analyses revealed that the changes in mean
maximum atheroma thickness were favorably affected by
RIO. However, changes in atheroma volume in the most
diseased 10-mm subsegments showed no significant dif-
ference between treatments. To clarify whether this sec-
ondary end point result can be translated into a clinical
benefit (eg, myocardial infarction, stroke, and cardio-
vascular death reduction), the CRESCENDO trial was
launched.29 The trial, however, was prematurely termi-
nated because of increasing concerns related to in-
creased anxiety and suicide rates in the RIO treatment
group. Additional trials are needed to clarify whether
modification of the ECS can lead to a clinically relevant
decrease in macrovascular complications of diabetes,
as soon as an effective peripheral CB1 receptor antag-
onist30 or a CB2 receptor agonist
4 reaches the clinical
phase of development.
Independent from macrovascular complications, dia-
betic cardiomyopathy is a distinct primary disease pro-
cess that leads to heart failure in diabetic patients. Dia-
betic cardiomyopathy is characterized by left ventricular
hypertrophy and diastolic dysfunction due to myocardial
collagen and advanced glycation end product deposi-
tion.64 ROS have been implicated in all stages of the
development of heart failure, including cardiac hypertro-
phy, fibrosis, and contractile dysfunction.65 The role of
the ECS in diabetic cardiomyopathy has not been inves-
tigated in detail, even though several studies have shown
the involvement of cannabinoid receptors in oxidative
stress–related cardiac dysfunction. CB1 receptors can
mediate oxidative stress and cell death in doxorubicin-
induced cardiomyopathy models and in human cardio-
myocytes66,67; this damage is enhanced in mice deficient
in the main EC, AEA-metabolizing enzyme, FAAH.54 CB1
receptor inhibition by RIO was also shown to be protec-
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AJP February 2012, Vol. 180, No. 2tive in a myocardial infarction model in which mice were
fed a standard or high-fat diet.68 In contrast, the activa-
tion of CB2 receptors showed cardioprotective effects,
69
which were mediated by three different mechanisms: re-
duced superoxide production, increased levels of extra-
cellular signal–regulated kinase 1/2 and signal trans-
ducer and activator of transcription-3 phosphorylation,
and inhibited neutrophil recruitment. Although direct in-
volvement of the ECS has not yet been proven in diabetic
cardiomyopathy, the plant-derived cannabinoid CBD at-
tenuates inflammation, oxidative stress, cell death, myo-
cardial dysfunction, and fibrosis in a diabetic cardiomy-
opathy model.14 These beneficial effects involve the
attenuation of diabetes-induced myocardial NF-B and
MAPK activation and the promotion of survival mecha-
nisms (eg, AKT/protein kinase B activation).
Diabetic Nephropathy
Diabetes is a leading cause of renal failure, accounting
for 44% of all new cases in 2008.18 Hyperglycemia stim-
ulates ROS generation, which ultimately leads (via di-
verse pathways) to diabetic nephropathy characterized
by mesangial expansion, thickening of the glomerular
basement membrane, and glomerular sclerosis.70 There
is strong evidence that both the synthetic and degrada-
tive pathways of the ECS are present in the kidney,71 and
the CB1 receptor is expressed in both glomeruli and
tubular epithelial cells.72 In intrarenal arteries, the CB1
receptor is present in the endothelium,72 and the CB2
receptor is present in mesangial cells.71 Cannabinoid
receptors play opposing roles in the regulation of oxida-
tive stress in the kidney, as observed in a murine ne-
phropathy model induced by cisplatin. The CB1 receptor
promotes inflammation, oxidative/nitrative stress, and cell
death through the activation of the p38-MAPK pathway.73
In contrast, CB2 receptor agonists limit damage after
cisplatin administration by reducing oxidative stress, in-
flammation, and apoptosis.74 For therapeutic purposes, it
is important that plant-derived CBD is also able to ame-
liorate cisplatin-induced nephrotoxicity.75
The first direct indication that the ECS plays an impor-
tant role in the pathogenesis of diabetic nephropathy
came from a murine model of metabolic syndrome.72
Blockade of CB1 receptors by RIO prolonged the lifespan
of obese Zucker rats, even at a dose that did not influ-
ence the development of obesity. This effect was concur-
rent with a delay in the progression of renal failure as
shown by the prevention of the development of protein-
uria, improved creatinine clearance, and reduction of
glomerular injury and renal hypertrophy compared with
vehicle-treated rats. Similarly, RIO was also able to re-
duce the albumin-creatinine ratio and glomerular sclero-
sis in a prediabetic rat model of metabolic syndrome.62
Definitive proof for the direct involvement of CB1 recep-
tors in diabetic nephropathy arose from a type 1 diabetic
model in which metabolic effects did not confound the
outcome.76 The CB1 receptor was found to be overex-
pressed by glomerular podocytes after streptozotocin
treatment. The selective CB1 antagonist AM-251 reduced
proteinuria by preventing a decrease in the mRNA andprotein levels of the slit diaphragm molecules nephrin,
podocin, and zonula occludens-1 in diabetic kidneys.76
Similar to the cisplatin-induced nephropathy model, an
opposing protective effect of CB2 receptor activation was
demonstrated in the type 1 diabetic nephropathy model.
CB2 agonists ameliorated albuminuria, podocyte protein
down-regulation, and glomerular monocyte infiltration
without affecting early markers of fibrosis and reduced
chemokine receptor-2 expression in both the renal cortex
and cultured podocytes, suggesting that CB2 receptor
activation may interfere with the deleterious effects of
MCP-1 signaling.77 Podocytes express the CB2 receptor
both in vitro and in vivo. The CB2 receptor was down-
regulated in kidney biopsy specimens from patients with
advanced diabetic nephropathy, and renal levels of the
CB2 ligand 2-AG were reduced in diabetic mice, sug-
gesting impaired CB2 signaling.
77
The in vivo results were supported by in vitro findings
that provided more mechanistic insight as to how the ECS
influences the pathogenesis of renal failure in diabetes
and the role of tubular processes in the effects of ECs
during the development of diabetic kidney damage. In
vitro, AEA significantly increases the hypertrophy of prox-
imal tubular cells.78 CB1 antagonists reduced and CB2
antagonists increased the observed hypertrophy. In an-
other study, the hyperlipidemia-induced tubular cell dys-
function observed in diabetic kidneys was modeled by
palmitic acid–induced apoptosis in HK-2 cells.79 In this
system, CB1 receptor overexpression was observed in a
cyclooxygenase-dependent manner. Blockade of CB1
receptors was able to ameliorate palmitic acid–induced
endoplasmic reticulum stress and the subsequent apop-
tosis. In rat mesangial cells, high glucose levels up-reg-
ulate CB1 mRNA expression levels and internalization in
NF-B– and cytosolic phospholipase A2–dependent
manners.80 CB1 antagonism prevented high glucose
concentration–induced apoptosis via the attenuation of
endoplasmic reticulum stress, providing further evidence
of the potential beneficial effects of CB1 receptor block-
ade in diabetic nephropathy.
Diabetic Retinopathy
Diabetes is the leading cause of new cases of blind-
ness and preventable blindness among adults. Vascu-
lar inflammation and endothelial cell death caused by
oxidative and nitrative stress are characteristics of di-
abetic retinopathy.21 In the early stages, retinopathy is
characterized by microaneurysm formation and micro-
vascular lesions and later by extensive intraretinal
hemorrhage that culminates in proliferative diabetic
retinopathy with neovascularization and either prereti-
nal or vitreous hemorrhage.81
The ECS is present in the retina as shown by the
presence of AEA, 2-AG, and the metabolizing enzymes
FAAH and MAGL.82 CB1 receptors are expressed in the
layers of the retina, ciliary body, iris, and choroid,
whereas CB2 receptors are localized to the retina.
83 It has
been shown that EC levels are elevated in the eyes of
patients with diabetic retinopathy.84 2-AG levels are ele-
vated in the iris, whereas AEA levels are increased in the
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such an increase gained importance when we received
insight into the role of CB1 receptor activation in diabetic
retinopathy. Deletion of the CB1 receptor or treatment
with a CB1 receptor antagonist prevented retinal cell
death in a murine diabetes model.85 Treatment of dia-
betic mice or human retinal cells with CB1 receptor an-
tagonists after exposure to high glucose levels attenu-
ated oxidative/nitrative stress, reduced NF-B activation
and adhesion molecule levels, and attenuated MAPK ac-
tivation. These observations were supported by the fact
that hyperglycemia up-regulated CB1 receptor expres-
sion and induced apoptosis in retina pigment epithelial
cells, effects that were preventable with a CB1 receptor
antagonist.86 Interestingly, hyperglycemia also de-
creased FAAH expression, leading to a locally increased
concentration of AEA and thereby increasing apoptosis
via CB1 receptor signaling.
The effect of CBD was also examined in experimental
diabetic retinopathy. CBD was able to reduce oxidative
stress, inflammation, cell death, and vascular hyperper-
meability associated with diabetes.12 Consistent with
these findings, CBD also inhibited p38-MAPK signaling.
Furthermore, CBD also attenuated high glucose–induced
endothelial cell dysfunction, ROS generation, and barrier
disruption in primary human coronary artery endothelial
cells.52 The protective effects of CBD on retinal cell death
were, at least in part, due to the reduction of tyrosine
nitration of glutamine synthase in macroglial cells,
Figure 1. Effects of CB1 receptor activation on diabetes and diabetic comp
directly enhance diabetes-associated inflammation and ROS generation, promotin
angiotensin II receptor type 1; CNS, central nervous system; PMNs, polymorphonucthereby preventing the accumulation and excitotoxicity of
glutamine through N-methyl-D-aspartate receptors.87
Diabetic Neuropathy
Approximately 60% to 70% of people with diabetes have
some kind of nervous system damage.18 The typical pre-
sentation is chronic, length-dependent sensorimotor neu-
ropathy, which develops in a background of long-stand-
ing hyperglycemia and is associated with alterations of
microvessels; it can be stabilized with rigorous glycemic
control.88 Autonomic dysfunction and pain may develop
over time as well.88,89
CB1 receptors are widely expressed throughout the cen-
tral and peripheral nervous systems, whereas CB2 recep-
tors are primarily restricted to the cells of the peripheral
nervous system, microglia, and dorsal horn neurons. ECs
are retrograde messengers with agonistic activity on pre-
synaptic CB1 receptors, slowing neurotransmission. A
good example of this effect is the suppression of nocice-
ptive transmission in the periphery at the level of the
posterior horn of the spinal cord.90 It has been proven
that these peripheral CB1 receptors play a key role in
cannabinoid-induced analgesia.91 Interestingly, although
CB1 and CB2 agonists are effective in animal models of
acute and chronic pain, in clinical trials, they only perform
well in patients with chronic pain syndrome.92 Sativex
spray containing THC and CBD is already approved for
the treatment of pain in patients with multiple sclerosis
. CB1 receptor activation may indirectly (via its metabolic consequences) orlications
g tissue injury and the development of diabetic complications. AT rec,
lear leukocytes.
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ada, the United Kingdom, and Spain.
The first indication of the role of the ECS in diabetic
neuropathy came from a murine diabetes model. A dual
CB1/CB2 receptor agonist inhibited capsaicin-induced
calcitonin gene–related peptide release, a measure of
sensory neuron function, which was prevented by a CB1
antagonist.93 AEA also inhibited capsaicin-induced cal-
citonin gene–related peptide release in a non-CB1/CB2
receptor–dependent fashion, which was interestingly
lacking in diabetic mice. Mechanical allodynia in diabetic
rats can also be attenuated by treatment with a nonse-
lective cannabinoid agonist.94 A highly significant finding
was that both CB1 and CB2 agonists demonstrated anti-
nociceptive effects in mice with streptozotocin-induced
diabetes, and there were no pronociceptive effects for
either CB1 or CB2 antagonists.
95 Even more promising is
(in terms of developing and using CB1 antagonists in the
Figure 2. Possible beneficial effects of CB2 receptor activation on diabete
against various diabetic complications by attenuating high glucose–induced
adhesion, and activation of inflammatory cells; and subsequent proinflammatory resp
vascular adhesion molecule-1.treatment of primary diabetes and diabetic complica-
tions) that subchronic CB1 receptor antagonism has
been shown to evoke a -opiate–dependent analgesia
by increasing the transcription of genes encoding the
opioid system in the spinal cord.96
Both in vitro and in vivo findings regarding the role of
cannabinoid receptors in the pathogenesis of diabetic
peripheral neuropathy are contradictory. CB1 receptor
expression has been shown to be down-regulated in
PC-12 cells exposed to high glucose levels and in dorsal
root ganglia removed from diabetic rats97; the synthetic
cannabinoid HU-210 was able to restore impaired nerve
growth factor–induced neurite outgrowth in cells exposed
to high glucose levels in a CB1 receptor–dependent
manner,98 consistent with the earlier finding that HU-210
attenuates neural damage.99 In vivo, however, the CB1
receptor antagonist RIO shows a beneficial effect in dia-
betic peripheral neuropathy.100,101 RIO improves de-
abetic complications. CB2 receptor stimulation may exert beneficial effects
elial cell activation and inflammatory response; chemotaxis, transmigration,s and di
endothonses and ROS generation. PMNs, polymorphonuclear leukocytes; VCAM-1,
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AJP February 2012, Vol. 180, No. 2creased intraepidermal nerve fiber density and alleviates
increased current perception threshold, which is closely
associated with the attenuation of skin capillary loss, in-
crease in blood flow, and reduction of TNF- levels.101
RIO also ameliorates mechanical allodynia in diabetic mice,
reduces oxidative stress in peripheral nerves, inhibits TNF-
overproduction in the spinal cord, and restores NGF con-
tent.100 The alleviation of mechanical allodynia with RIOwas
attributed to diminished sensitization of the transient re-
ceptor potential vanilloid receptor via CB1 receptor an-
tagonism.102
In summary, CB1 receptor antagonism appears to be a
viable option for halting the progression of diabetic neu-
ropathy and may provide some analgesic effects through
a -opiate–dependent pathway. The natural cannabinoid
CBD offers a further possible therapeutic advantage be-
cause it was able to attenuate the development of neu-
ropathic pain. This effect was associated with the restric-
tion in the elevations of microglial density in the spinal
cord and of phosphorylated p38-MAPK.95 The first clini-
cal trial with Sativex has already been conducted in pa-
tients with painful diabetic neuropathy.103 Although the
trial failed to show any advantage compared with pla-
cebo treatment, further analysis is needed because sev-
eral confounding factors were present.
Conclusion and Perspectives
Although there is much controversy in the field of EC
research, experimental evidence and clinical trials have
clearly shown that ECS plays a key role in the develop-
ment of primary diabetes and various diabetic complica-
tions. Although inhibition of CB1 receptors has proven to
be effective in clinical trials of obesity and metabolic
syndrome, this approach has ultimately failed because of
increasing patient anxiety. However, recent preclinical
studies clearly showed that peripherally restricted CB1
antagonists may represent a viable therapeutic strategy
to avoid the previously mentioned adverse effects.25,30
Importantly, CB1 inhibition, as discussed in this review,
may also directly attenuate inflammatory responses and
ROS and reactive nitrogen species generation in endo-
thelial, immune, and other cell types, as well as in target
tissues of diabetic complications, far beyond its known
beneficial metabolic consequences. The main effects of
CB1 receptor activation on the development of diabetes
and diabetic complications are summarized in Figure 1.
CB2 agonists may exert beneficial effects on diabetes
and diabetic complications by attenuating inflammatory
response and ensuing oxidative stress (Figure 2). Natural
cannabinoids, such as CBD and THCV, also have tre-
mendous therapeutic potential. CBD is a potent antioxi-
dant and anti-inflammatory agent that does not appear to
exert its beneficial effects through conventional CB re-
ceptors104 and is already approved for human use. THCV
and its derivatives, which may combine the beneficial
effects of simultaneous CB1 inhibition and CB2 stimula-
tion, are still under intense preclinical investigation. It will
be interesting to see how newly developed, peripherally
restricted CB1 receptor antagonists and/or CB2 receptoragonists and certain natural cannabinoids, such as CBD
and THCV, will influence the clinical outcomes of diabetic
patients. We hope that some of these new approaches
will be useful in clinical practice in the near future to aid
patients with diabetes.
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